ADAM17

Across TCGA pan-cancer cohorts, ADAM17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADAM17 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ADAM17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM17 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where ADAM17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.688	0.969	.001	54	view →
PDAC	DFS	Quartile	All	0.616	0.837	.001	29	view →
LSCC	DFS	Tertile	All	0.512	1.000	.030	7	view →
HNSC	OS	Tertile	All	1.000	0.936	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADAM17–CCRCC (OS)

Open the CCRCC breakdown →